1887

Chapter 27 : Cytomegalovirus

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.

Ebook: Choose a downloadable PDF or ePub file. Chapter is a downloadable PDF file. File must be downloaded within 48 hours of purchase

Buy this Chapter
Digital (?) $30.00

Preview this chapter:
Zoom in
Zoomout

Cytomegalovirus, Page 1 of 2

| /docserver/preview/fulltext/10.1128/9781555819156/9781555819149.ch27-1.gif /docserver/preview/fulltext/10.1128/9781555819156/9781555819149.ch27-2.gif

Abstract:

Cytomegalovirus (CMV) is one of 8 known herpesviruses to infect humans. Classified as a β-herpesvirus, along with human herpesvirus-6 and human herpesvirus-7, CMV is a large virus that was first isolated in humans from salivary glands in the 1950s (1). Since its discovery, CMV has been linked to a multitude of clinical syndromes in humans and is possibly the most important virus of clinical consequence among immunocompromised patients and pregnant women.

Citation: Pancholi P, Martin S. 2016. Cytomegalovirus, p 373-385. In Loeffelholz M, Hodinka R, Young S, Pinsky B (ed), Clinical Virology Manual, Fifth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555819156.ch27
Highlighted Text: Show | Hide
Loading full text...

Full text loading...

References

/content/book/10.1128/9781555819156.ch27
1. Smith MG. 1956. Propagation in tissue cultures of a cytopathogenic virus from human salivary gland virus (SGV) disease. Proc Soc Exp Biol Med 92:424430[CrossRef].[PubMed]
2. Chee MS, Bankier AT, Beck S, Bohni R, Brown CM, Cerny R, Horsnell T, Hutchison CA, Kouzarides T, Martignetti JA, Preddie E, Satchwell SC, Tomlinson P, Weston KM, Barrell BG. 1990. Analysis of the protein-coding content of the sequence of human cytomegalovirus strain AD169. Curr Top Microbiol Immunol 154:125169[CrossRef].[PubMed]
3. Kalejta RF. 2008. Tegument proteins of human cytomegalovirus. Microbiol Mol Biol Rev 72:249265[CrossRef].[PubMed]
4. Lurain NS, Kapell KS, Huang DD, Short JA, Paintsil J, Winkfield E, Benedict CA, Ware CF, Bremer JW. 1999. Human cytomegalovirus UL144 open reading frame: sequence hypervariability in low-passage clinical isolates. J Virol 73:1004010050.[PubMed]
5. Miller-Kittrell M, Sparer TE. 2009. Feeling manipulated: cytomegalovirus immune manipulation. Virol J 6:4[CrossRef].[PubMed]
6. Plachter B, Sinzger C, Jahn G. 1996. Cell types involved in replication and distribution of human cytomegalovirus. Adv Virus Res 46:195261[CrossRef].[PubMed]
7. Krech U. 1973. Complement-fixing antibodies against cytomegalovirus in different parts of the world. Bull World Health Organ 49:103106.[PubMed]
8. Staras SA, Dollard SC, Radford KW, Flanders WD, Pass RF, Cannon MJ. 2006. Seroprevalence of cytomegalovirus infection in the United States, 1988-1994. Clin Infect Dis 43:11431151[CrossRef].[PubMed]
9. Bate SL, Dollard SC, Cannon MJ. 2010. Cytomegalovirus seroprevalence in the United States: the national health and nutrition examination surveys, 1988-2004. Clin Infect Dis 50:14391447[CrossRef].[PubMed]
10. Ross SA, Arora N, Novak Z, Fowler KB, Britt WJ, Boppana SB. 2010. Cytomegalovirus reinfections in healthy seroimmune women. J Infect Dis 201:386389[CrossRef].[PubMed]
11. Boppana SB, Rivera LB, Fowler KB, Mach M, Britt WJ. 2001. Intrauterine transmission of cytomegalovirus to infants of women with preconceptional immunity. N Engl J Med 344:13661371[CrossRef].[PubMed]
12. Kenneson A, Cannon MJ. 2007. Review and meta-analysis of the epidemiology of congenital cytomegalovirus (CMV) infection. Rev Med Virol 17:253276[CrossRef].[PubMed]
13. Dollard SC, Grosse SD, Ross DS. 2007. New estimates of the prevalence of neurological and sensory sequelae and mortality associated with congenital cytomegalovirus infection. Rev Med Virol 17:355363[CrossRef].[PubMed]
14. Stagno S, Whitley RJ. 1985. Herpesvirus infections of pregnancy. Part I: cytomegalovirus and Epstein-Barr virus infections. N Engl J Med 313:12701274[CrossRef].[PubMed]
15. Hoover DR, Saah AJ, Bacellar H, Phair J, Detels R, Anderson R, Kaslow RA. 1993. Clinical manifestations of AIDS in the era of pneumocystis prophylaxis. Multicenter AIDS Cohort Study. N Engl J Med 329:19221926[CrossRef].[PubMed]
16. Sugar EA, Jabs DA, Ahuja A, Thorne JE, Danis RP, Meinert CL Studies of the Ocular Complications of AIDS Research Group. 2012. Incidence of cytomegalovirus retinitis in the era of highly active antiretroviral therapy. Am J Ophthalmol 153:101624.e5[CrossRef].[PubMed]
17. Kusne S, Shapiro R, Fung J. 1999. Prevention and treatment of cytomegalovirus infection in organ transplant recipients. Transpl Infect Dis 1:187203[CrossRef].[PubMed]
18. Khoury JA, Storch GA, Bohl DL, Schuessler RM, Torrence SM, Lockwood M, Gaudreault-Keener M, Koch MJ, Miller BW, Hardinger KL, Schnitzler MA, Brennan DC. 2006. Prophylactic versus preemptive oral valganciclovir for the management of cytomegalovirus infection in adult renal transplant recipients. Am J Transplant 6:21342143[CrossRef].[PubMed]
19. Marr KA. 2012. Delayed opportunistic infections in hematopoietic stem cell transplantation patients: a surmountable challenge. Hematology (Am Soc Hematol Educ Program) 2012:265270.[PubMed]
20. Gluckman E, Traineau R, Devergie A, Esperou-Bourdeau H, Hirsch I. 1992. Prevention and treatment of CMV infection after allogeneic bone marrow transplant. Ann Hematol 64(Suppl):A158A161[CrossRef].[PubMed]
21. Ozdemir E, Saliba RM, Champlin RE, Couriel DR, Giralt SA, de Lima M, Khouri IF, Hosing C, Kornblau SM, Anderlini P, Shpall EJ, Qazilbash MH, Molldrem JJ, Chemaly RF, Komanduri KV. 2007. Risk factors associated with late cytomegalovirus reactivation after allogeneic stem cell transplantation for hematological malignancies. Bone Marrow Transplant 40:125136[CrossRef].[PubMed]
22. Klemola E, Von Essen R, Henle G, Henle W Clinical Features in Relation to Epstein-Barr Virus and Cytomegalovirus Antibodies. 1970. Infectious-mononucleosis-like disease with negative heterophil agglutination test. Clinical features in relation to Epstein-Barr virus and cytomegalovirus antibodies. J Infect Dis 121:608614[CrossRef].[PubMed]
23. Horwitz CA, Henle W, Henle G, Snover D, Rudnick H, Balfour HH Jr, Mazur MH, Watson R, Schwartz B, Muller N. 1986. Clinical and laboratory evaluation of cytomegalovirus-induced mononucleosis in previously healthy individuals. Report of 82 cases. Medicine (Baltimore) 65:124134[CrossRef].[PubMed]
24. Eddleston M, Peacock S, Juniper M, Warrell DA. 1997. Severe cytomegalovirus infection in immunocompetent patients. Clin Infect Dis 24:5256[CrossRef].[PubMed]
25. Papadakis KA, Tung JK, Binder SW, Kam LY, Abreu MT, Targan SR, Vasiliauskas EA. 2001. Outcome of cytomegalovirus infections in patients with inflammatory bowel disease. Am J Gastroenterol 96:21372142[CrossRef].[PubMed]
26. Limaye AP, Kirby KA, Rubenfeld GD, Leisenring WM, Bulger EM, Neff MJ, Gibran NS, Huang ML, Santo Hayes TK, Corey L, Boeckh M. 2008. Cytomegalovirus reactivation in critically ill immunocompetent patients. JAMA 300:413422[CrossRef].[PubMed]
27. Hanshaw JB, Scheiner AP, Moxley AW, Gaev L, Abel V, Scheiner B. 1976. School failure and deafness after “silent” congenital cytomegalovirus infection. N Engl J Med 295:468470[CrossRef].[PubMed]
28. Goderis J, De Leenheer E, Smets K, Van Hoecke H, Keymeulen A, Dhooge I. 2014. Hearing loss and congenital CMV infection: a systematic review. Pediatrics 134:972982[CrossRef].[PubMed]
29. Gallant JE, Moore RD, Richman DD, Keruly J, Chaisson RE The Zidovudine Epidemiology Study Group. 1992. Incidence and natural history of cytomegalovirus disease in patients with advanced human immunodeficiency virus disease treated with zidovudine. J Infect Dis 166:12231227[CrossRef].[PubMed]
30. Kotton CN. 2013. CMV: Prevention, diagnosis and therapy. Am J Transplant 13(Suppl 3):2440, quiz 40[CrossRef].[PubMed]
31. Fishman JA, Emery V, Freeman R, Pascual M, Rostaing L, Schlitt HJ, Sgarabotto D, Torre-Cisneros J, Uknis ME. 2007. Cytomegalovirus in transplantation - challenging the status quo. Clin Transplant 21:149158[CrossRef].[PubMed]
32. Pescovitz M. 2006. Valganciclovir: what is the status in solid organ transplantation? Future Virol 1:147156[CrossRef].
33. Owers DS, Webster AC, Strippoli GF, Kable K, Hodson EM. 2013. Pre-emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ transplant recipients. Cochrane Database Syst Rev 2:CD005133.[PubMed]
34. Manuel O, Kralidis G, Mueller NJ, Hirsch HH, Garzoni C, van Delden C, Berger C, Boggian K, Cusini A, Koller MT, Weisser M, Pascual M, Meylan PR Swiss Transplant Cohort Study. 2013. Impact of antiviral preventive strategies on the incidence and outcomes of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 13:24022410[CrossRef].[PubMed]
35. Kalil AC, Levitsky J, Lyden E, Stoner J, Freifeld AG. 2005. Meta-analysis: the efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients. Ann Intern Med 143:870880[CrossRef].[PubMed]
36. Asberg A, Humar A, Rollag H, Jardine AG, Mouas H, Pescovitz MD, Sgarabotto D, Tuncer M, Noronha IL, Hartmann A VICTOR Study Group. 2007. Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 7:21062113[CrossRef].[PubMed]
37. Martin DF, Sierra-Madero J, Walmsley S, Wolitz RA, Macey K, Georgiou P, Robinson CA, Stempien MJ Valganciclovir Study Group. 2002. A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis. N Engl J Med 346:11191126[CrossRef].[PubMed]
38. Smith CL. 1998. Local therapy for cytomegalovirus retinitis. Ann Pharmacother 32:248255[CrossRef].[PubMed]
39. Florescu DF, Keck MA. 2014. Development of CMX001 (Brincidofovir) for the treatment of serious diseases or conditions caused by dsDNA viruses. Expert Rev Anti Infect Ther 12:11711178[CrossRef].[PubMed]
40. Härter G, Michel D. 2012. Antiviral treatment of cytomegalovirus infection: an update. Expert Opin Pharmacother 13:623627[CrossRef].[PubMed]
41. Stoelben S, Arns W, Renders L, Hummel J, Mühlfeld A, Stangl M, Fischereder M, Gwinner W, Suwelack B, Witzke O, Dürr M, Beelen DW, Michel D, Lischka P, Zimmermann H, Rübsamen-Schaeff H, Budde K. 2014. Preemptive treatment of Cytomegalovirus infection in kidney transplant recipients with letermovir: results of a Phase 2a study. Transpl Int 27:7786[CrossRef].[PubMed]
42. Chemaly RF, Ullmann AJ, Stoelben S, Richard MP, Bornhäuser M, Groth C, Einsele H, Silverman M, Mullane KM, Brown J, Nowak H, Kölling K, Stobernack HP, Lischka P, Zimmermann H, Rübsamen-Schaeff H, Champlin RE, Ehninger G AIC246 Study Team. 2014. Letermovir for cytomegalovirus prophylaxis in hematopoietic-cell transplantation. N Engl J Med 370:17811789[CrossRef].[PubMed]
43. Kharfan-Dabaja MA, Boeckh M, Wilck MB, Langston AA, Chu AH, Wloch MK, Guterwill DF, Smith LR, Rolland AP, Kenney RT. 2012. A novel therapeutic cytomegalovirus DNA vaccine in allogeneic haemopoietic stem-cell transplantation: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Infect Dis 12:290299[CrossRef].[PubMed]
44. Pass RF, Zhang C, Evans A, Simpson T, Andrews W, Huang ML, Corey L, Hill J, Davis E, Flanigan C, Cloud G. 2009. Vaccine prevention of maternal cytomegalovirus infection. N Engl J Med 360:11911199[CrossRef].[PubMed]
45. Schultz DA, Chandler S. 1991. Cytomegalovirus testing: antibody determinations and virus cultures with recommendations for use. J Clin Lab Anal 5:6973[CrossRef].[PubMed]
46. Cytomegalovirus (CMV) and Congenital CMV Infection. Interpretation of Laboratory Tests. http://www.cdc.gov/cmv/clinical/lab-tests.html (accessed 8/19/14).
47. Dollard SC, Staras SA, Amin MM, Schmid DS, Cannon MJ. 2011. National prevalence estimates for cytomegalovirus IgM and IgG avidity and association between high IgM antibody titer and low IgG avidity. Clin Vaccine Immunol 18:18951899[CrossRef].[PubMed].
48. Bate SL, Dollard SC, Cannon MJ. 2010. Cytomegalovirus seroprevalence in the United States: the national health and nutrition examination surveys, 1988-2004. Clin Infect Dis 50:14391447[CrossRef].[PubMed]
49. Weber B, Fall EM, Berger A, Doerr HW. 1999. Screening of blood donors for human cytomegalovirus (HCMV) IgG antibody with an enzyme immunoassay using recombinant antigens. J Clin Virol 14:173181[CrossRef].[PubMed]
50. Seed CR, Piscitelli LM, Maine GT, Lazzarotto T, Doherty K, Stricker R, Stricker R, Iriarte B, Patel C. 2009. Validation of an automated immunoglobulin G-only cytomegalovirus (CMV) antibody screening assay and an assessment of the risk of transfusion transmitted CMV from seronegative blood. Transfusion 49:134145[CrossRef].[PubMed]
51. Lazzarotto T, Brojanac S, Maine GT, Landini MP. 1997. Search for cytomegalovirus-specific immunoglobulin M: comparison between a new western blot, conventional western blot, and nine commercially available assays. Clin Diagn Lab Immunol 4:483486.[PubMed]
52. Humar A, Mazzulli T, Moussa G, Razonable RR, Paya CV, Pescovitz MD, Covington E, Alecock E Valganciclovir Solid Organ Transplant Study Group. 2005. Clinical utility of cytomegalovirus (CMV) serology testing in high-risk CMV D+/R− transplant recipients. Am J Transplant 5:10651070[CrossRef].[PubMed]
53. Kotton CN, Kumar D, Caliendo AM, Asberg A, Chou S, Danziger-Isakov L, Humar A. 2013. Transplantation Society International CMV Consensus Group. Updated international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. Transplantation. 96(4):333360.
54. Ross SA, Novak Z, Pati S, Boppana SB. 2011. Overview of the diagnosis of cytomegalovirus infection. Infect Disord Drug Targets 11:466474[CrossRef].[PubMed]
55. Patel R, Klein DW, Espy MJ, Harmsen WS, Ilstrup DM, Paya CV, Smith TF. 1995. Optimization of detection of cytomegalovirus viremia in transplantation recipients by shell vial assay. J Clin Microbiol 33:29842986[PubMed].
56. Boeckh M, Huang M, Ferrenberg J, Stevens-Ayers T, Stensland L, Nichols WG, Corey L. Optimization of quantitative detection of cytomegalovirus DNA in plasma by real-time PCR. 2004. J Clin Microbiol. 42(3):11421148.
57. Razonable RR, Humar A AST Infectious Diseases Community of Practice. 2013. Cytomegalovirus in solid organ transplantation. Am J Transplant 13(Suppl 4):93106[CrossRef].[PubMed]
58. Chemaly RF, Yen-Lieberman B, Castilla EA, Reilly A, Arrigain S, Farver C, Avery RK, Gordon SM, Procop GW. 2004. Correlation between viral loads of cytomegalovirus in blood and bronchoalveolar lavage specimens from lung transplant recipients determined by histology and immunohistochemistry. J Clin Microbiol 42:21682172[CrossRef].[PubMed]
59. Solans EP, Yong S, Husain AN, Eichorst M, Gattuso P. 1997. Bronchioloalveolar lavage in the diagnosis of CMV pneumonitis in lung transplant recipients: an immunocytochemical study. Diagn Cytopathol 16:350352[CrossRef].[PubMed]
60. Ljungman P, Griffiths P, Paya C. 2002. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 34:10941097[CrossRef].[PubMed]
61. Halme L, Lempinen M, Arola J, Sarkio S, Höckerstedt K, Lautenschlager I. 2008. High frequency of gastroduodenal cytomegalovirus infection in liver transplant patients. APMIS 116:99106[CrossRef].[PubMed]
62. van der Bij W, Schirm J, Torensma R, van Son WJ, Tegzess AM, The TH. 1988. Comparison between viremia and antigenemia for detection of cytomegalovirus in blood. J Clin Microbiol 26:25312535.[PubMed]
63. Schröeder R, Michelon T, Fagundes I, Bortolotto A, Lammerhirt E, Oliveira J, Santos A, Bittar A, Keitel E, Garcia V, Neumann J, Saitovitch D. 2005. Antigenemia for cytomegalovirus in renal transplantation: choosing a cutoff for the diagnosis criteria in cytomegalovirus disease. Transplant Proc 37:27812783[CrossRef].[PubMed]
64. Baldanti F, Lilleri D, Gerna G. 2008. Monitoring human cytomegalovirus infection in transplant recipients. J Clin Virol 41:237241[CrossRef].[PubMed]
65. Gerna G, Baldanti F, Lilleri D, Parea M, Torsellini M, Castiglioni B, Vitulo P, Pellegrini C, Viganò M, Grossi P, Revello MG. 2003. Human cytomegalovirus pp67 mRNAemia versus pp65 antigenemia for guiding preemptive therapy in heart and lung transplant recipients: a prospective, randomized, controlled, open-label trial. Transplantation 75:10121019[CrossRef].[PubMed]
66. Saracino A, Colucci R, Latorraca A, Muscaridola N, Procida C, Di Noia I, Santospirito VE, Santarsia G. 2013. The effects of preemptive therapy using a very low threshold of pp65 antigenemia to prevent cytomegalovirus disease in kidney transplant recipients: a single-center experience. Transplant Proc 45:182184[CrossRef].[PubMed]
67. Cardeñoso L, Pinsky BA, Lautenschlager I, Aslam S, Cobb B, Vilchez RA, Hirsch HH. 2013. CMV antigenemia and quantitative viral load assessments in hematopoietic stem cell transplant recipients. J Clin Virol 56:108112[CrossRef].[PubMed]
68. Razonable RR, Hayden RT. 2013. Clinical utility of viral load in management of cytomegalovirus infection after solid organ transplantation. Clin Microbiol Rev. 26(4):703–727.
69. Boeckh M, Huang M, Ferrenberg J, Stevens-Ayers T, Stensland L, Nichols WG, Corey L. 2004. Optimization of quantitative detection of cytomegalovirus DNA in plasma by real-time PCR. J Clin Microbiol. 42(3):1142–1148.
70. Pang XL, Fox JD, Fenton JM, Miller GG, Caliendo AM, Preiksaitis JK American Society of Transplantation Infectious Diseases Community of Practice, Canadian Society of Transplantation. 2009. Interlaboratory comparison of cytomegalovirus viral load assays. Am J Transplant 9:258268[CrossRef].[PubMed]
71. Fryer JF, Heath AB, Anderson R, Minor PD. 2010. Collaborative study to evaluate the proposed 1st WHO International Standard for human cytomegalovirus (HCMV) for nucleic acid amplification (NAT)-based assays. WHOECBS (Expert Committee on Biological Standardization) Report. WHO/BS/10.2138.
72. Kraft CS, Armstrong WS, Caliendo AM. 2012. Interpreting quantitative cytomegalovirus DNA testing: understanding the laboratory perspective. Clin Infect Dis 54:17931797[CrossRef].[PubMed]
73. Razonable RR, Åsberg A, Rollag H, Duncan J, Boisvert D, Yao JD, Caliendo AM, Humar A, Do TD. 2013. Virologic suppression measured by a cytomegalovirus (CMV) DNA test calibrated to the World Health Organization international standard is predictive of CMV disease resolution in transplant recipients. Clin Infect Dis. 56(11):1546–1553.
74. Hayden RT, Gu Z, Ingersoll J, Abdul-Ali D, Shi L, Pounds S, Caliendo AM. 2013. Comparison of droplet digital PCR to real-time PCR for quantitative detection of cytomegalovirus. J Clin Microbiol 51:540546[CrossRef].[PubMed]
75. COBAS® AmpliPrep/COBASO TaqMan® CMV Test (Roche Molecular Systems, Inc. Branchburg, NJ: 2013). COBAS TaqMan CMV Test FDA approved package insert. http://www.accessdata.fda.gov/cdrh_docs/pdf11/P110037c.pdf
76. artus® CMV RGQ MDx Kit Test (Qiagen:2014). COBAS TaqMan CMV Test FDA approved package insert. http://www.accessdata.fda.gov/cdrh_docs/pdf13/P130027c.pdf
77. Kerschner H, Bauer C, Schlag P, Lee S, Goedel S, Popow-Kraupp T. 2011. Clinical evaluation of a fully automated CMV PCR assay. J Clin Virol. 50(4):281–286.
78. Hirsch HH, Lautenschlager I, Pinsky BA, Cardeñoso L, Aslam S, Cobb B, Vilchez RA, Valsamakis A. 2013. An international multicenter performance analysis of cytomegalovirus load tests. Clin Infect Dis 56:367373[CrossRef].[PubMed]
79. Caliendo AM. 2013. The long road toward standardization of viral load testing for cytomegalovirus. Clin Infect Dis 56:374375[CrossRef].[PubMed]
80. Lisboa LF, Asberg A, Kumar D, Pang X, Hartmann A, Preiksaitis JK, Pescovitz MD, Rollag H, Jardine AG, Humar A. 2011. The clinical utility of whole blood versus plasma cytomegalovirus viral load assays for monitoring therapeutic response. Transplantation 91:231236[CrossRef].[PubMed]
81. Razonable RR, Brown RA, Wilson J, Groettum C, Kremers W, Espy M, Smith TF, Paya CV. 2002. The clinical use of various blood compartments for cytomegalovirus (CMV) DNA quantitation in transplant recipients with CMV disease. Transplantation 73:968973[CrossRef].[PubMed]
82. Tang W, Elmore SH, Fan H, Thorne LB, Gulley ML. 2008. Cytomegalovirus DNA measurement in blood and plasma using Roche LightCycler CMV quantification reagents. Diagn Mol Pathol 17:166173[CrossRef].[PubMed]
83. Salmon-Céron D, Mazeron MC, Chaput S, Boukli N, Senechal B, Houhou N, Katlama C, Matheron S, Fillet AM, Gozlan J, Leport C, Jeantils V, Freymuth F, Costagliola D. 2000. Plasma cytomegalovirus DNA, pp65 antigenaemia and a low CD4 cell count remain risk factors for cytomegalovirus disease in patients receiving highly active antiretroviral therapy. AIDS 14:10411049[CrossRef].[PubMed]
84. Erice A, Tierney C, Hirsch M, Caliendo AM, Weinberg A, Kendall MA, Polsky B AIDS Clinical Trials Group Protocol 360 Study Team. 2003. Cytomegalovirus (CMV) and human immunodeficiency virus (HIV) burden, CMV end-organ disease, and survival in subjects with advanced HIV infection (AIDS Clinical Trials Group Protocol 360). Clin Infect Dis 37:567578[CrossRef].[PubMed]
85. Westall GP, Michaelides A, Williams TJ, Snell GI, Kotsimbos TC. 2004. Human cytomegalovirus load in plasma and bronchoalveolar lavage fluid: a longitudinal study of lung transplant recipients. J Infect Dis 190:10761083[CrossRef].[PubMed]
86. Chemaly RF, Yen-Lieberman B, Chapman J, Reilly A, Bekele BN, Gordon SM, Procop GW, Shrestha N, Isada CM, Decamp M, Avery RK. 2005. Clinical utility of cytomegalovirus viral load in bronchoalveolar lavage in lung transplant recipients. Am J Transplant 5:544548[CrossRef].[PubMed]
87. Wiita AP, Roubinian N, Khan Y, Chin-Hong PV, Singer JP, Golden JA, Miller S. 2012. Cytomegalovirus disease and infection in lung transplant recipients in the setting of planned indefinite valganciclovir prophylaxis. Transpl Infect Dis 14:248258[CrossRef].[PubMed]
88. Riise GC, Andersson R, Bergström T, Lundmark A, Nilsson FN, Olofsson S. 2000. Quantification of cytomegalovirus DNA in BAL fluid: a longitudinal study in lung transplant recipients. Chest 118:16531660[CrossRef].[PubMed]
89. Emery VC, Sabin CA, Cope AV, Gor D, Hassan-Walker AF, Griffiths PD. 2000. Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation. Lancet 355 (9220):20322036.
90. Egli A, Humar A, Kumar D. 2012. State-of-the-art monitoring of cytomegalovirus-specific cell-mediated immunity after organ transplant: a primer for the clinician. Clin Infect Dis. 55(12):1678–1689.
91. Schmidt T, Schub D, Wolf M, Dirks J, Ritter M, Leyking S, Singh M, Zawada AM, Blaes-Eise AB, Samuel U, Sester U, Sester M. 2014. Comparative analysis of assays for detection of cell-mediated immunity toward cytomegalovirus and M. tuberculosis in samples from deceased organ donors. Am J Transplant. Jul 10.
92. Abate D, Saldan A, Mengoli C, Fiscon M, Silvestre C, Fallico L, Peracchi M, Furian L, Cusinato R, Bonfante L, Rossi B, Marchini F, Sgarabotto D, Rigotti P, Palù G. 2013. Comparison of cytomegalovirus (CMV) enzyme-linked immunosorbent spot and CMV quantiferon gamma interferon-releasing assays in assessing risk of CMV infection in kidney transplant recipients. J Clin Microbiol. 51(8):2501-2507.
93. Manuel O, Husain S, Kumar D, Zayas C, Mawhorter S, Levi ME, Kalpoe J, Lisboa L, Ely L, Kaul DR, Schwartz BS, Morris MI, Ison MG, Yen-Lieberman B, Sebastian A, Assi M, Humar A. 2013. Assessment of cytomegalovirus-specific cell-mediated immunity for the prediction of cytomegalovirus disease in high-risk solid-organ transplant recipients: a multicenter cohort study. Clin Infect Dis 56:817824[CrossRef].[PubMed]
94. Gilbert C, Boivin G. 2005. Human cytomegalovirus resistance to antiviral drugs. Antimicrob Agents Chemother 49:873883[CrossRef].[PubMed]
95. Göhring K, Wolf D, Bethge W, Mikeler E, Faul C, Vogel W, Vöhringer MC, Jahn G, Hamprecht K. 2013. Dynamics of coexisting HCMV-UL97 and UL54 drug-resistance associated mutations in patients after haematopoietic cell transplantation. J Clin Virol: 57: 4349.
96. Hakki M, Chou S. 2011. The biology of cytomegalovirus drug resistance. Curr Opin Infect Dis 24:605611[CrossRef].[PubMed]
97. Sahoo MK, Lefterova MI, Yamamoto F, Waggoner JJ, Chou S, Holmes SP, Anderson MW, Pinsky BA. 2013. Detection of cytomegalovirus drug resistance mutations by next-generation sequencing. J Clin Microbiol 51:37003710[CrossRef].[PubMed]
98. Chou S, Ercolani RJ, Sahoo MK, Lefterova MI, Strasfeld LM, Pinsky BA. 2014. Improved detection of emerging drug-resistant mutant cytomegalovirus subpopulations by deep sequencing. Antimicrob Agents Chemother 58:46974702[CrossRef].[PubMed]
99. Chou S. 1990. Newer methods for diagnosis of cytomegalovirus infection. Rev Infect Dis 12(Suppl 7):S727S736[CrossRef].[PubMed]
100. Lazzarotto T, Spezzacatena P, Pradelli P, Abate DA, Varani S, Landini MP. 1997. Avidity of immunoglobulin G directed against human cytomegalovirus during primary and secondary infections in immunocompetent and immunocompromised subjects. Clin Diagn Lab Immunol 4:469473.[PubMed]
101. Liesnard C, Donner C, Brancart F, Gosselin F, Delforge ML, Rodesch F. 2000. Prenatal diagnosis of congenital cytomegalovirus infection: prospective study of 237 pregnancies at risk. Obstet Gynecol 95:881888[CrossRef].[PubMed]
102. Azam AZ, Vial Y, Fawer CL, Zufferey J, Hohlfeld P. 2001. Prenatal diagnosis of congenital cytomegalovirus infection. Obstet Gynecol 97:443448[CrossRef].[PubMed]
103. Nelson CT, Istas AS, Wilkerson MK, Demmler GJ. 1995. PCR detection of cytomegalovirus DNA in serum as a diagnostic test for congenital cytomegalovirus infection. J Clin Microbiol 33:33173318.[PubMed]
104. Demmler GJ, Buffone GJ, Schimbor CM, May RA. 1988. Detection of cytomegalovirus in urine from newborns by using polymerase chain reaction DNA amplification. J Infect Dis 158:11771184[CrossRef].[PubMed]
105. Jabs DA, Gilpin AM, Min YI,. Erice A, Kempen JH, Quinn TC. 2002. HIV and cytomegalovirus viral load and clinical outcomes in AIDS and cytomegalovirus retinitis patients: Monoclonal Antibody Cytomegalovirus Retinitis Trial. AIDS 16:877-887.
106. Group SOC. 1997. Cytomegalovirus (CMV) culture results, drug resistance, and clinical outcome in patients with AIDS and CMV retinitis treated with foscarnet or ganciclovir. Studies of Ocular Complications of AIDS (SOCA) in collaboration with the AIDS Clinical Trial Group. J Infect Dis 176:5058[CrossRef].[PubMed]
107. Spector SA, Wong R, Hsia K, Pilcher M, Stempien MJ. 1998. Plasma cytomegalovirus (CMV) DNA load predicts CMV disease and survival in AIDS patients. J Clin Invest 101:497502[CrossRef].[PubMed]
108. Knapp AB, Horst DA, Eliopoulos G, Gramm HF, Gaber LW, Falchuk KR, Falchuk ZM, Trey C. 1983. Widespread cytomegalovirus gastroenterocolitis in a patient with acquired immunodeficiency syndrome. Gastroenterology 85:13991402.[PubMed]
109. Wallace JM, Hannah J. 1987. Cytomegalovirus pneumonitis in patients with AIDS. Findings in an autopsy series. Chest 92:198203[CrossRef].[PubMed]
110. Mann M, Shelhamer JH, Masur H, Gill VJ, Travis W, Solomon D, Manischewitz J, Stock F, Lane HC, Ognibene FP. 1997. Lack of clinical utility of bronchoalveolar lavage cultures for cytomegalovirus in HIV infection. Am J Respir Crit Care Med 155:17231728[CrossRef].[PubMed]
111. Arribas JR, Clifford DB, Fichtenbaum CJ, Commins DL, Powderly WG, Storch GA. 1995. Level of cytomegalovirus (CMV) DNA in cerebrospinal fluid of subjects with AIDS and CMV infection of the central nervous system. J Infect Dis 172:527531[CrossRef].[PubMed]
112. Boivin G, Goyette N, Rollag H, Jardine AG, Pescovitz MD, Asberg A, Ives J, Hartmann A, Humar A. 2009. Cytomegalovirus resistance in solid organ transplant recipients treated with intravenous ganciclovir or oral valganciclovir. Antivir Ther 14:697704.[PubMed]

Tables

Generic image for table
TABLE 1

Laboratory Tests for Cytomegalovirus Detection

Citation: Pancholi P, Martin S. 2016. Cytomegalovirus, p 373-385. In Loeffelholz M, Hodinka R, Young S, Pinsky B (ed), Clinical Virology Manual, Fifth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555819156.ch27

This is a required field
Please enter a valid email address
Please check the format of the address you have entered.
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error